Scientific Evidence
A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management
Apr 2024
Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.
Publication: Future Medicine
Utility of 31-gene expression profile test in identifying patients with T1 cutaneous melanoma at high risk of SLN positivity and recurrence
Mar 2024
Demonstrate that the 31-GEP offers significant prognostic value in addition to SLN status to help identify patients at the highest risk of tumor recurrence.
Publication: ePoster at SSO 2024
Prospecive validation of the i31-GEP for cutaneous melanoma to select patients who may consider foregoing SLNB
Mar 2024
This study shares three-year outcomes data from Castle’s prospective, multicenter study of patients with melanoma who were being considered for an SLNB (n=322). In the study, at three years, all patients with a low-risk DecisionDx-Melanoma test result were recurrence free (recurrence free survival of 100%). The performance data shared in this presentation, in conjunction with previous validation and performance studies, show DecisionDx-Melanoma as an accurate and precise clinical tool that can identify patients who may safely forego SLNB, reducing the number of unnecessary SLNBs performed (by ~25% in this study alone) and the associated costs and risks of complications that accompany them.
Publication: Oral Presentation at SSO 2024
The 31-gene expression profile test outperforms AJCC in stratifying risk of recurrence in patients with stage I cutaneous melanoma
Jan 2024
In a head-to-head comparison of DecisionDx-Melanoma to AJCCv8 staging for stage I cutaneous melanoma (CM) patients (n=6,883) two cohorts were analyzed using recurrence-free survival and melanoma-specific survival. Results from the study showed that DecisionDx-Melanoma significantly improved patient risk stratification, independent of AJCC staging in patients. In addition, DecisionDx-Melanoma provided greater separation between high-risk (Class 2B) and low-risk (Class 1A) groups than seen between AJCC stage IA and IB.
Publication: Cancers
Diagnostic utility of the 23-gene expression profile test for an atypical intradermal melanocytic proliferation
Dec 2023
A case report describing how MyPath GEP testing leads to diagnostic clarity in a histopathologically ambiguous melanocytic lesion on the face of a 34-year-old man.
Publication: Future Medicine
A physician’s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms
Dec 2023
Publication: Journal of Clinical and Aesthetic Dermatology
A Physician’s Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms
Dec 2023
A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.
Publication: Journal of Clinical and Aesthetic Dermatology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms
Nov 2023
Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions
Publication: Skin
31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration
Jun 2023
Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.
Publication: JCO-PO
Asymmetrical pigmented lesion with high clinical suspicion for melanoma
Jun 2023
A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.
Multi-colored lesion with uncertain malignant potential
Jun 2023
Conflicting clinical and histopathological findings are resolved with the use of GEP test results.
Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis
Jun 2023
Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.